IceCure Medical Ltd ICCM
As ofNov 20, 2026, 12:38 PM EST
- YTD
- -95.63%
- 1 year
- -95.89%
5D +0.3138 (+45.92%)
- Market cap
- 4.45M
- Revenue (ttm)
- 3.34M
- EPS (ttm)
- -6.84
- Shares out
- 55.50M
- Forward P/E
- -4.48
- YTD return
- -95.63%
- 1-year return
- -95.89%
- 50-day average
- 0.74766
- Volume
- 115.64K
- Avg volume
- 184.53K
- Open
- 0.8498
- Previous close
- 0.9971
- Day's range
- 0.80 – 0.8561
- 52-week range
- 0.65 – 22.20
- Beta
- 2.63
- Price target
- 3.37 (+320.8%)
Key statistics
- 200-day average
- 0.852735
- Enterprise value
- 28.55M
- Price / sales
- 18.63
- Price / book
- 4.21
- Revenue growth
- 7.90%
- Free cash flow
- -6.62M
- Total cash
- 10.46M
- Total debt
- 520.00K
- Return on equity
- -94.22%
- Short % of float
- 0.98%
Fundamental scorecard
8 of 25 checks passed on ICCM’s reported financials
8of 25 checks passed
- Value 2 of 5
- Growth 2 of 5
- Profitability 1 of 5
- Financial health 3 of 5
- Dividend No data
Statements to Jun 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 26, 2024 | Sep 1, 2024 | -0.07 | -0.08 | -0.01 | -14.29% |
| Aug 20, 2024 | Jun 1, 2024 | -0.07 | — | — | — |
| Aug 20, 2024 | Jun 1, 2024 | -0.07 | -0.06 | +0.01 | +14.29% |
| May 28, 2024 | Mar 1, 2024 | -0.08 | — | — | — |
| May 28, 2024 | Mar 1, 2024 | -0.08 | -0.08 | 0.00 | 0.00% |
| Apr 3, 2024 | Dec 1, 2023 | 0.00 | -0.07 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 8, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 12, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 21, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 5, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About IceCure Medical Ltd
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- Israel
- Website
- icecure-medical.com
News
IceCure: 3 Key Takeaways for Long-Term Investors
IceCure Medical Ltd (ICCM) Q3 2026 Earnings Call Transcript
12 Health Care Stocks Moving In Wednesday's Intraday Session
IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates Icecure Medical Q3 EPS $(0.40) Beats $(1.16) Estimate, Sales $824.000K Miss $876.500K Estimate
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2026: 83% Year-Over-Year Growth in U.S. Sales and Major Growth in U.S. Commercial Reach to 21 States IceCure Medical Receives New Patent In China For Covering A Connector Used In Its Cryogenic Technology Platform
IceCure Medical Completes Treatment Of First Patient In Its Post-Marketing Study Evaluating ProSense Cryoablation For Local Treatment Of Low-Risk Breast Cancer
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Your note
Sign in to keep a note on ICCM — it syncs with the Stock Master app.
